|
| | SB2046 Engrossed | | LRB097 10049 KTG 50225 b |
|
|
1 | | AN ACT concerning public aid.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Public Aid Code is amended by |
5 | | changing Section 5-5.12 as follows:
|
6 | | (305 ILCS 5/5-5.12) (from Ch. 23, par. 5-5.12)
|
7 | | Sec. 5-5.12. Pharmacy payments.
|
8 | | (a) Every request submitted by a pharmacy for reimbursement |
9 | | under this
Article for prescription drugs provided to a |
10 | | recipient of aid under this
Article shall include the name of |
11 | | the prescriber or an acceptable
identification number as |
12 | | established by the Department.
|
13 | | (b) Pharmacies providing prescription drugs under
this |
14 | | Article shall be reimbursed at a rate which shall include
a |
15 | | professional dispensing fee as determined by the Illinois
|
16 | | Department, plus the current acquisition cost of the |
17 | | prescription
drug dispensed. The Illinois Department shall |
18 | | update its
information on the acquisition costs of all |
19 | | prescription drugs
no less frequently than every 30 days. |
20 | | However, the Illinois
Department may set the rate of |
21 | | reimbursement for the acquisition
cost, by rule, at a |
22 | | percentage of the current average wholesale
acquisition cost.
|
23 | | (c) (Blank).
|
|
| | SB2046 Engrossed | - 2 - | LRB097 10049 KTG 50225 b |
|
|
1 | | (d) The Department shall not impose requirements for prior |
2 | | approval
based on a preferred drug list for anti-retroviral, |
3 | | anti-hemophilic factor
concentrates,
or
any atypical |
4 | | antipsychotics, conventional antipsychotics,
or |
5 | | anticonvulsants used for the treatment of serious mental
|
6 | | illnesses
until 30 days after it has conducted a study of the |
7 | | impact of such
requirements on patient care and submitted a |
8 | | report to the Speaker of the
House of Representatives and the |
9 | | President of the Senate. The Department shall review |
10 | | utilization of narcotic medications in the medical assistance |
11 | | program and impose utilization controls that protect against |
12 | | abuse.
|
13 | | (e) When making determinations as to which drugs shall be |
14 | | on a prior approval list, the Department shall include as part |
15 | | of the analysis for this determination, the degree to which a |
16 | | drug may affect individuals in different ways based on factors |
17 | | including the gender of the person taking the medication. |
18 | | (f) The Department shall cooperate with the Department of |
19 | | Public Health and the Department of Human Services Division of |
20 | | Mental Health in identifying psychotropic medications that, |
21 | | when given in a particular form, manner, duration, or frequency |
22 | | (including "as needed") in a dosage, or in conjunction with |
23 | | other psychotropic medications to a nursing home resident, may |
24 | | constitute a chemical restraint or an "unnecessary drug" as |
25 | | defined by the Nursing Home Care Act or Titles XVIII and XIX of |
26 | | the Social Security Act and the implementing rules and |
|
| | SB2046 Engrossed | - 3 - | LRB097 10049 KTG 50225 b |
|
|
1 | | regulations. The Department shall require prior approval for |
2 | | any such medication prescribed for a nursing home resident that |
3 | | appears to be a chemical restraint or an unnecessary drug. The |
4 | | Department shall consult with the Department of Human Services |
5 | | Division of Mental Health in developing a protocol and criteria |
6 | | for deciding whether to grant such prior approval. |
7 | | (g) The Department may by rule provide for reimbursement of |
8 | | the dispensing of a 90-day supply of a generic or brand name , |
9 | | non-narcotic maintenance medication in circumstances where it |
10 | | is cost effective. |
11 | | (Source: P.A. 96-1269, eff. 7-26-10; 96-1372, eff. 7-29-10; |
12 | | 96-1501, eff. 1-25-11.)
|